Please read the abstract on page 3 in the dissertation. / Dissertation (MSc)--University of Pretoria, 2011. / Chemical Pathology / unrestricted

Inflammatory processes in, or in close vicinity of, the skeleton often lead to loss of bone tissue. Different cytokines have been shown to be involved as stimulators of inflammatory induced osteoclastic bone resorption. During inflammatory processes also the kallikrein-kinin system is activated, leading to production of kinins that can cause pain, vasodilation and increased permeability of vessels. Kinins can also induce bone resorption in vitro. All cytokines and kinins that stimulate bone resorption stimulate in parallell prostaglandin synthesis, and prostaglandins, per se, have also been shown to induce bone resorption. The aim of this project was to increase the knowledge about the mechanisms involved in the interactions between different inflammatory mediators (i.e. kinins, cytokines and prostaglandins) suggested to be involved in the pathogenesis of inflammatory bone resorbing diseases. Human osteoblasts (MG-63) are equipped with both kinin B1 and B2 receptors linked to prostaglandin release and the stimulation of prostaglandin release are likely mediated via separate molecular mechanisms (Paper I). Activation of B1 or B2 receptors causes synergistic stimulation of PGE2 synthesis induced by either interleukin-1b (IL-1b) or tumour necrosis factor-a (TNF-a) (Paper II). The molecular mechanism involves increased expression of cyclooxygenase-2 (COX-2) and results in synergistic potentiation of receptor activator of NF-kB ligand (RANKL) protein expression. The synergistic interaction is dependent on the activation of NF-kB and the mitogen-activated protein kinases (MAPK) p38 and JNK (Paper II). The synergistic increase in RANKL expression might be an explanation why kinins potentiate IL-1b induced bone resorption, a mechanism likely to be important in inflammation induced bone resorption in diseases such as periodontal disease and rheumatoid arthritis. The synergism between kinins and IL-1b or TNF-a might also be dependent on regulation of kinin receptors, since both IL-1b and TNF-a markedly upregulated B1 and B2 receptors, both at the mRNA level and protein level (Paper III). This upregulation is not further potentiated by the kinins, and different kinin receptor agonists do not regulate the receptors for IL-1b or TNF-a, in MG-63 cells. No other cytokines known to stimulate bone resorption regulates the expressions of B1 and B2 receptors. The IL-1b- or TNF-a-induced enhancements of B1 and B2 receptor expressions involve activation of NF-kB and MAPK. The enhancement of kinin receptors may also be an important mechanism in the synergistic interactions between the two pro-inflammatory cytokines and kinins (paper III). IL-4 and IL-13 are two cytokines that have been shown to inhibit bone resorption. We have shown that COX-2 and both B1 and B2 receptors are down-regulated by IL-4 and IL-13, via a ‘signal transducer and activator of transcription6’ (STAT6) dependent pathway, which might be an important regulatory mechanism in inflammation induced bone resorption (paper IV). In conclusion, the mechanisms behind the synergistic potentiation of prostaglandin formation and increased bone resorption caused by co-stimulation with kinins and IL-1b or TNF-a seem to involve both potentiation of COX-2 and subsequently increased levels of RANKL, as well as upregulation of B1 and B2 kinin receptors. Interestingly, IL-4 and IL-13 decreased the expressions of COX-2 and both B1 and B2 receptors. These events might be important in the regulation of inflammation induced bone resorption in diseases such as periodontitis and rheumatoid arthritis.

This study focused on the role of RANKL in prostate cancer EMT progression and metastasis. Activation of RANK, a receptor activator of NF-kB, by its ligand RANKL, in a paracrine manner is responsible for osteoclast differentiation and bone remodeling. RANK activation in cancer cells, however, is thought to be promoted by both autocrine and paracrine mechanisms because RANKL has been shown to be derived from either tumor or its microenvironment, such as osteoblasts, infiltrating inflammatory cells and stromal fibroblasts. In the present study, we demonstrated that autocrine and paracrine RANKL-RANK signaling could be responsible for driving prostate cancer bone metastasis by promoting epithelial to mesenchymal transition (EMT). We further characterized a novel converging RANKL-c-Met signaling network in which the activation of RANKL was found to promote the expression of both RANKL and c-Met in an autocrine manner in prostate cancer cells. The induced RANKL and c-Met in prostate cancer cells is biologically functional and contributes to increased osteoclastogenesis, epithelial to mesenchymal transition (EMT), cell motility, migration and invasion and conferred bone and soft tissue metastases. Remarkably, RANKL expression by 1,000 prostate cancer cells can provoke bone and soft tissue metastases of a “dormant” population of prostate cancer cells which by themselves failed to form tumors and colonize mouse skeleton, suggesting RANKL can serve as a factor in “reawakening” cancer dormancy to initiate the re-growth and metastasis of cancer cells. We also showed that RANKL-induced RANKL feed-forward autocrine regulation is mediated through cMyc transactivation, allowing the establishment of a “vicious cycle” further promoting prostate cancer growth and metastasis. The converging RANKL-c-Met signaling network is therefore a novel target that could be further manipulated for delaying the lethal progression of castration-resistant human prostate cancer bone metastasis.

Με τον όρο «Έκτοπη Οστεοποίηση» περιγράφεται ο σχηματισμός οστού σε σημεία που υπό φυσιολογικές συνθήκες δεν υφίσταται. Τα σημεία αυτά μπορεί να είναι μύες, τένοντες ή σύνδεσμοι και γενικότερα μεσεγχυματικού τύπου μαλακά μόρια, κυρίως γύρω από τις μεγαλύτερες αρθρώσεις. Η επίκτητη μορφή της νόσου, που είναι και η πιο κοινή, εμφανίζεται μετά από μυοσκελετικούς τραυματισμούς, κακώσεις του νωτιαίου μυελού και του κεντρικού νευρικού συστήματος γενικότερα, αλλά και σε περιπτώσεις σοβαρών εγκαυμάτων. Η παθοφυσιολογία της έκτοπης οστεοποίησης παραμένει άγνωστη, αυτό που γνωρίζουμε με βεβαιότητα είναι ότι για τον σχηματισμό της απαιτούνται τρείς βασικές προϋποθέσεις που είναι α) τα οστεοπρογονικά κύτταρα, β) οι κατάλληλοι επαγωγικοί παράγοντες και γ) το ευνοϊκό οστεοεπαγωγικό περιβάλλον. Στην παρούσα εργασία με την χρήση κυτταρομετρίας ροής, δοκιμασιών με ηλεκτροχημειοφωταύγεια, Elisa και ανοσοπροσδιορισμού με χρήση Cytometric Bead Array προσδιορίσαμε τις συγκεντρώσεις των total procollagen type 1 amino-terminal propeptide (TP1NP), osteoprotegerin (OPG), β-isomerized C-terminal telopeptides (β- Crosslaps), soluble receptor activator of nuclear factor kappa-B ligand (sRANKL), N-MID osteocalcin, S100 και των κυτταροκινών IL-2, IL-4, IL-6, IL-10, INF-γ και TNF-a στον ορό ασθενών και υγιών μαρτύρων. Επιπλέον, στο ολικό αίμα προσδιορίσαμε τον πληθυσμό των θετικών στην οστεοκαλσίνη κυττάρων. Όλα τα προς μελέτη μόρια είχαν άμεση ή έμμεση σχέση με την οστική ανακατασκευή και τις φλεγμονώδεις αντιδράσεις. Συνολικά μελετήθηκαν 55 ασθενείς από τους οποίους ελήφθησαν δείγματα καθόλη την διάρκεια νοσηλείας τους. Οι ασθενείς μελετήθηκαν με βάση το είδος του τραύματος, την εμφάνιση ή όχι έκτοπης οστεοποίησης και την έκβαση της κατάστασης τους. Επιπλέον, οι επιμέρους ομάδες ασθενών μελετήθηκαν συναρτήσει του χρόνου. Τα αποτελέσματα μας έδειξαν ότι στο σύνολο των ασθενών παρατηρήθηκαν στατιστικά μειωμένα επίπεδα β- crosslaps, N-MID osteocalcin, sRANKL και S100 συγκριτικά με τους υγιείς μάρτυρες. Αντίθετα, τα επίπεδα των TP1NP, των θετικών στην οστεοκαλσίνη κυττάρων, της OPG, της INF-γ και της IL-6 ήταν στατιστικά σημαντικά αυξημένα. Επιπλέον, στατιστικά σημαντικά αυξημένα παρατηρήθηκαν τα επίπεδα του S100 στους ασθενείς που είχαν υποστεί κρανιοεγκεφαλικές κακώσεις κατά το πρώτο εικοσιτετράωρο μετά την επαγωγή της κάκωσης. Στατιστικά σημαντικά αυξημένο επίσης παρατηρήθηκε και στην ομάδα των ασθενών με κακή έκβαση συγκριτικά με τους υγιείς δότες. Στην ίδια ομάδα ασθενών παρατηρήθηκε μια γενικευμένη αύξηση των επιπέδων των κυτταροκινών που φαίνεται να σχετίζεται άμεσα με την κακή έκβαση της κατάστασης τους. Πιο συγκεκριμένα η αύξηση αυτή ήταν στατιστικώς σημαντική για τις IL-4, INF-γ και TNF-α. / Heterotopic ossification (HO) is the presence of bone in soft tissue where normally does not exist. The acquired form, which is also the most common, develops after musculoskeletal trauma, spinal cord injury or central nervous system injury and severe burns. Pathophysiology of OH still remains unclear, what we know is that the formation of ectopic bone requires three entities which are a) osteogenic precursor cells, b) inducing agents and c) an appropriate environment. In the present study using either flow cytometry, Elisa, electrochemiluminescence immunoassays or cytometric bead array assays we determined the concentrations of the osteoblast progenitors: osteocalcin positive cells in peripheral blood and the serum concentrations of total procollagen type 1 amino-terminal propeptide (TP1NP), osteoprotegerin (OPG), β-isomerized C-terminal telopeptides (β- Crosslaps), soluble receptor activator of nuclear factor kappa-B ligand (sRANKL), N-MID osteocalcin, S100 and the cytokines IL-2, IL-4, IL-6, IL-10, INF-γ and TNF-a. All measured molecules participate directly or indirectly in bone formation and metabolism and in inflammation. Our 55 patients were divided and studied in 3 different ways, regarding the kind of their injury, their outcome and the formation of HO. They were also monitored in course of time. Among our most interesting results is that patients had significantly lower levels of β- crosslaps, N-MID osteocalcin, sRANKL and S100 compared to healthy donors. On the other hand, levels of TP1NP, osteocalcin positive cells, OPG, INF-γ and IL-6 were significantly higher. S100 is significantly increased during the first 24 hours in patients who have sustained traumatic brain injury. In addition, S100 was significantly increased in patients with poor outcome compared to healthy donors. Furthermore, patients with poor outcome seem to develop a cytokine storm which is of great importance for their outcome. All measured cytokine levels were increased compared to patients with good outcome. Especially for IL-4, INF-γ, TNF-α this increase was statistically significant.

Made available in DSpace on 2014-06-11T19:32:59Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-03-31Bitstream added on 2014-06-13T18:44:46Z : No. of bitstreams: 1 sartori_r_dr_arafo.pdf: 1126976 bytes, checksum: b952e5d8db014ff996192d8476649c74 (MD5) / Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) / Embora a doença periodontal tenha origem infecciosa, ela se caracteriza por uma complexa resposta imune-inflamatória, com a participação de células residentes e não-residentes, produzindo diversas citocinas e mediadores biológicos. A principal característica da doença periodontal destrutiva é a reabsorção do osso alveolar, a qual é uma consequência frequentemente irreversível do processo patológico e das citocinas produzidas pela resposta do hospedeiro. Citocinas específicas atuam diretamente no controle da remodelação óssea, denominadas RANKL (Receptor activator of NF-kB ligand) e OPG (Osteoprotegerin,). RANKL é uma proteína produzida por fibroblastos, osteoblastos, condrócitos, células mesenquimais e células T e B ativadas e sua ligação com o seu receptor RANK (Receptor activator of NF-kB) em células precursoras de osteoclastos é necessário e suficiente para a ativação, diferenciação e sobrevivência de osteoclastos maduros. OPG, a outra proteína envolvida nesta modulação, serve como um falso receptor para RANKL, impedindo dessa forma a ligação RANKL-RANK e levando a uma menor ativação de osteoclastos. Assim, o balanço entre RANKL e OPG é o atual paradigma para a modulação da remodelação óssea. FK-506 (tacrolimo) é uma droga imunossupressora usada para prevenir rejeição de enxertos afetando a ativação de linfócitos T por meio da modulação da via da calcineurina, inibindo a ativação de NFAT e de NF-kB. Estudos prévios demonstraram que o uso de tacrolimo em ratos diminui a resposta inflamatória e reabsorção óssea em modelo experimental de indução de doença periodontal. A proposta deste estudo foi avaliar os efeitos da administração sistêmica do tacrolimo sobre a expressão de RANKL e OPG na doença periodontal induzida em ratos e determinar in vitro, se o tratamento de células residentes do periodonto com tacrolimo... / Periodontitis is a well-characterized infectious disease with a complex immune-inflammatory response. In response to the bacterial presence, many resident and non-resident cells into the peridontium produce many cytokines and biologic mediators, causing tissue destruction and alveolar bone loss. These cytokines are the key-factor in osteoclast-mediated bone resorption. The expression ratio between two cytokines is fundamental to bone resorption process: RANKL (Receptor activator of NF-kB ligand) that is necessary to osteoclast differentiation, activation and survival, and OPG (Osteoprotegerin) that acts as the endogenous inhibitor of RANKL by functioning as its decoy receptor. RANKL is expressed by fibroblasts, osteoblasts, chondrocytes, mesenchymal cells and T and B lymphocytes. OPG is secreted primarily by osteoblastic cells, bone marrow stromal celss and fibroblasts and it counter regulates the excessive bone loss antagonizing the RANKL-binding to its receptor RANK in osteoclast precursor cells. The ratio between RANKL and OPG is the current paradigm for modulation of coupled bone turnover. FK-506 is an immunossupressive drug used to reduce and to prevent the risk of organ transplant rejections. It acts affecting T lymphocyte activation by calcinaurin pathway modulation inhibiting NFAT and NF-kB translocation to the nucleus. Previous studies showed that animals with experimental periodontitis treated with FK-506 exhibited less bone resorption and inflammatory infiltrate. The purpose of this study was evaluated effects of FK-506 systemic administration over RANKL and OPG expression in animals with experimental periodontitis; and determines if FK-506-treated periodontium resident cells can affect IL-1- and LPS-induced RANKL and OPG expression. In the in vivo study, two experimental periodontitis models were used (LPS and ligature) in rats. In the test group the animals received dail... (Complete abstract click electronic access below)

Breast cancer is the most common malignancy among women and represents a serious health problem around the world. Despite of the progression in cancer research, there is a few biomarker validated to be used in clinical routine. Thus, this work aimed to investigate the levels of four serum proteins related with the mostly earlier events of breast cancer. For this purpose, serum levels of EGFR1, HER-2, TSP-1 and RANKL were investigated in twenty-eight patients with breast cancer in the early and advanced stage by ELISA method. Nineteen volunteers with no breast cancer were included in this study as controls. The results showed that serum EGFR1 (sEGFR1) levels decrease with disease progression. The mean sEGFR1 concentration in control group was 61.7 ng/mL, 38.0 ng/mL in initial breast cancer and 34.2 ng/mL in metastatic breast cancer. The best cutoff value was 46.85 ng/mL, it was able to distinguish volunteers and breast cancer patients with 75% sensitivity, and 94.7% specificity. Regarding sHER-2, its levels were found to increase with disease progression. Serum HER-2 (sHER-2) median in control group was 5.13 ng/mL, and in initial breast, and metastatic breast cancer women the mean was 5.99 ng/mL and 6.18 ng/mL, respectively. A cutoff value of 5.38 ng/mL of HER-2 was able to distinguish healthy and breast cancer individuals with 81.5% of sensitivity and 78.9% of specificity. Regarding TSP-1, women with metastatic breast cancer had significantly lower levels than control group and initial breast cancer. Besides although initial patients tend to have a higher concentration than control group, no statistical difference was observed. Concerning serum RANKL no differences was observed between the groups. In conclusion, our results bring evidence that sEGFR1 and sHER-2 should be investigated in a large clinical trial in an attempt to validate these proteins as potentials biomarkers for earlier detection of breast cancer. / O câncer de mama é a neoplasia maligna mais comum entre as mulheres e representa um sério problema de saúde pública em todo o mundo. Apesar dos avanços em pesquisas na área de cancerologia, há poucos biomarcadores validados para uso na rotina clínica. Assim, este trabalho teve como objetivo investigar os níveis de quatro proteínas do soro relacionadas com os eventos em sua maioria anteriores do câncer de mama. Para este efeito, os níveis séricos de EGFR1, HER-2, TSP-1 e RANKL foram investigados em vinte e oito pacientes com câncer de mama em estádio inicial e avançado, pelo método de ELISA. Dezenove voluntárias sem câncer de mama foram incluídas neste estudo como grupo controle. Os resultados mostraram que os níveis séricos de EGFR1 (sEGFR1) diminui com a progressão da doença. A concentração média de sEGFR1 no grupo controle foi de 61,7 ng/mL, 38,0 ng/mL no câncer de mama inicial e 34,2 ng/mL no câncer de mama metastático. O melhor valor de cutoff foi 46,85 ng/mL, com sensibilidade de 75% e 94,7% de especificidade para distinguir entre pacientes com câncer de mama e grupo controle. Com relação ao sHER-2, as concentrações foram encontradas para aumentar com a progressão da doença. A concentração mediana de sHER-2 no grupo de controle foi de 5,13 ng/mL, e em pacientes com a neoplasia em sua fase inicial e com câncer de mama metastático a mediana foi de 5,99 ng/mL e 6,18 ng/mL, respectivamente. Um valor de cutoff de 5,38 ng/mL de HER-2 foi capaz de distinguir indivíduos saudáveis e de câncer de mama, com 81,5% de sensibilidade e 78,9% de especificidade. Quanto à sTSP-1, mulheres com câncer de mama metastático têm níveis mais baixos do que o grupo controle e pacientes com câncer inicial. Além disso, embora as pacientes iniciais tendessem a ter uma concentração mais elevada do que o grupo controle, não houve diferença estatística. Quanto ao sRANKL nenhuma diferença foi observada entre os grupos. Por último, os nossos resultados trazem evidências de que os níveis de sEGFR1 e sHER-2 devem ser investigados em ensaios clínicos com tamanho amostral significativo na tentativa de se validar estas proteínas como potenciais biomarcadores para a detecção precoce do câncer de mama. / Mestre em Imunologia e Parasitologia Aplicadas

Indiana University-Purdue University Indianapolis (IUPUI) / PTH increases osteoclasts by upregulating RANKL in cells of the osteoblastic lineage, but the precise differentiation stage of the PTH target cell remains undefined. Recent findings demonstrate that PTH regulates gene expression in osteocytes and that these cells are an important source of RANKL. We therefore investigated whether direct regulation of the RANKL gene by PTH in osteocytes is required to stimulate osteoclastic bone resorption. To address this question, we examined bone resorption and RANKL expression in transgenic mice in which PTH receptor signaling is activated only in osteocytes (DMP1-caPTHR1) crossed with mice lacking the distal control region regulated by PTH in the RANKL gene (DCR -/-). Longitudinal analysis of circulating C-terminal telopeptide (CTX) in male mice showed elevated resorption in growing mice that progressively decreased to plateau at 3-5 month of age. Resorption was significantly higher (~100%) in DMP1-caPTHR1 mice and non-significantly lower (15-30%) in DCR -/-mice, versus wild type littermates (WT) across all ages. CTX in compound DMP1-caPTHR1; DCR -/-mice was similar to DMP1-caPTHR1 mice at 1 and 2 months of age, but by 3 months of age, was significantly lower compared to DMP1-caPTHR1 mice (50% higher than WT), and by 5 months, it was undistinguishable from WT mice. Micro-CT analysis revealed lower tissue material density in the distal femur of DMP1-caPTHR1 mice, indicative of high remodeling, and this effect was partially corrected in compound vi mice. The increased resorption exhibited by DMP1-caPTHR1 mice was accompanied by elevated RANKL mRNA in bone at 1 and 5 months of age. RANKL expression levels displayed similar patterns to CTX levels in DMP1-caPTHR1; DCR -/-compound mice at 1 and 5 month of age. The same pattern of expression was observed for M-CSF. We conclude that resorption induced by PTH receptor signaling requires direct regulation of the RANKL gene in osteocytes, but this dependence is age specific. Whereas DCR-independent mechanisms involving gp130 cytokines or vitamin D 3 might operate in the growing skeleton, DCR-dependent, cAMP/PKA/CREB-activated mechanisms mediate resorption induced by PTH receptor signaling in the adult skeleton.

Το αξιόπιστο πειραματικό μοντέλο της ωοθηκεκτομής σε επίμυες εφαρμόστηκε για τη μελέτη των παθογενετικών μηχανισμών της οστεοπόρωσης. Σκοπός της παρούσας διδακτορικής διατριβής ήταν η διερεύνηση του ρόλου της λεπτίνης και των κυτοκινών RANKL και οστεοπροτεγερίνης (OPG) στην εξέλιξη της οστεοπόρωσης. Για την διεκπεραίωση της μελέτης χρησιμοποιήθηκαν 40 ενήλικοι θηλυκοί επίμυες ηλικίας 9 μηνών. Πριν την ωοθηκεκτομή στους επίμυες εφαρμόστηκε η τεχνική της ποσοτικής υπολογιστικής τομογραφίας (pQCT) παράλληλα με την πρωτοποριακή μη επεμβατική τεχνική του θερμοδυναμικού συντελεστή εσωτερικής απόσβεσης (MDF) ώστε να διαπιστωθεί η κατάσταση της οστικής πυκνότητας των πειραματόζωων. Σε χρονικά διαστήματα 20, 40 και 60 ημερών μετά την ωοθηκεκτομή πραγματοποιήθηκαν τυχαίες ομαδικές θυσίες με σκοπό τη συλλογή αίματος και την απομόνωση μηριαίων οστών και οστών κνήμης. Την 60η ημέρα πριν τη θυσία στην τελευταία ομάδα των ωοθηκεκτομήθέντων επίμυων επαναλήφθηκαν οι μετρήσεις pQCT και MDF για να διαπιστωθεί η εγκατάσταση σοβαρής οστεοπόρωσης με τη λήξη της πειραματικής πορείας. Οι οροί αίματος που συλλέχθηκαν από όλα τα χρονικά πειραματικά σημεία χρησιμοποιήθηκαν για τη διερεύνηση των επιπέδων έκφρασης των βιοχημικών δεικτών του οστικού μεταβολισμού NTx και οστεοκαλσίνης καθώς και της ελεύθερης λεπτίνης με την τεχνική της ενζυμικής ανοσοπροσρόφησης (ELISA). Στα οστά της κνήμης εφαρμόστηκε η τεχνική της ιστομορφομετρίας για τη μελέτη των μεταβολών της μικροαρχιτεκτονικής δομής των οστών κατά την εξέλιξη της οστεοπόρωσης. Επιπρόσθετα η τεχνική της ανοσοϊστοχημείας εφαρμόστηκε στα οστά της κνήμης για τη διερεύνηση των μεταβολών που προκαλεί η ωοθηκεκτομή στα επίπεδα έκφρασης του υποδοχέα της λεπτίνης και των κυτοκινών RANKL και οστεοπροτεγερίνης στους οστικούς κυτταρικούς πληθυσμούς. Στα μηριαία οστά εφαρμόστηκαν οι τεχνικές της ηλεκτροφόρησης σε πηκτή πολυακρυλαμιδίου (SDS-PAGE electrophoresis) και του ανοσοστυπώματος (Western Blot) για να συλλεχθούν επιπλέον πληροφορίες σχετικά με τις μεταβολές στα επίπεδα έκφρασης του υποδοχέα της λεπτίνης και των κυτοκινών RANKL και οστεοπροτεγερίνης κατά την εξέλιξη της οτεοπόρωσης. Τα συμπεράσματα που διεξάγονται από τα επιμέρους πειραματικά δεδομένα επιβεβαιώνουν την υπόθεση ότι η λεπτίνη κατέχει σημαντικό ρόλο στη ρύθμιση του οστικού μεταβολισμού και συμμετέχει ενεργά μέσω κάποιου άγνωστου μέχρι στιγμής μηχανισμού στη διαδικασία της οστικής ανακατασκευής στην οστεοπόρωση. Όσον αφορά τις ρυθμιστικές κυτοκίνες της οστεοκλαστογένεσης RANKL και OPG, διαπιστώθηκε ότι μεταβάλλονται σημαντικά κατά την εξέλιξη της οστεοπόρωσης στους ωοθηκεκτομηθέντες επίμυες, υποδηλώνοντας τη σημαντικότητα του ρόλου τους στον οστικό μεταβολισμό. / Ovariectomy in mature rats mimics the changes in bone metabolism observed in postmenopausal women and results in osteoporosis. The aim of this thesis was to investigate the role of leptin and the cytokine RANKL and Osteoprotegerin (OPG) in the progression of ovariectomy-induced osteoporosis. Nine–month-old female Wistar rats were bilaterally ovariectomized (n=40). Before the operation, pQCT and MDF technology were applied on rats in order to estimate the bone mineral density of the animals. On days 20, 40 and 60 after the operation the rats were randomly sacrificed and blood samples, dissected knees and femurs were collected. On day 60, pQCT and MDF techniques were applied in order to confirm the establishment of severe osteoporosis until the end of the experimental procedure. Leptin, and the biochemical markers of bone metabolism, osteocalcin and NTx, were measured in blood serum from all time points, by an ELISA method. Bone sections from the knees of the rats were examined by histomorphometric techniques in order to investigate the alterations in the micro-architectural structure of the skeleton caused by ovariectomy. Furthermore, immunohistochemistry was applied on knee sections and SDS-PAGE electrophoresis and western blot techniques were performed in femur homogenized tissueς, in order to investigate whether the expression levels of leptin receptor, RANKL and OPG were altered during the progression of osteoporosis. The results indicate that leptin is involved in the molecular mechanisms of bone remodeling in osteoporosis. The regulators of osteoclastogenesis, RANKL and OPG are also important players in the field of bone metabolism

No description available.

Made available in DSpace on 2014-12-17T15:32:29Z (GMT). No. of bitstreams: 1 KaruzaMAP_Tese.pdf: 829792 bytes, checksum: 60cd145c0f060b54f7dfbb5463648200 (MD5) Previous issue date: 2010-02-25 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior / The Giant Cell Lesions, both the Central Giant Cells Lesions (CGCL) as the Peripheral Giant Cells Lesions (PGCL), correspond to a group of oral lesions that are histologically similar entities; however they show a variable clinical behaviour. The purpose of this study was to compare the immunohistochemical expression of bone resorption factors RANK (Receptor Activator of Nuclear Factor kappa B), RANKL (Receptor Activator of Nuclear Factor kappa B Ligand) and OPG (Osteoprotegerin) between CGCL and PGCL. Additionally, these bone resorption factors were examined in terms of aggressiveness of these lesions. The sample consisted of 61 cases, 30 cases of PGCL and 31 CGCL (16 non-aggressive and 15 aggressive). The analysis was performed by quantification of mononuclear cells (MO) and giant multinucleated cells (CG) immunopositive to anti-RANK, anti-RANKL and anti-OPG antibodies in 10 fields. Moreover, according to the proportion between the amount of cells positive for RANKL and OPG, the cases were categorized into: RANKL>OPG, OPG>RANKL e RANKL=OPG. CGCL showed a higher amount of MO (p=0.002) and total cells (p=0.003) both positives to RANKL compared with the PGCL. Additionally, the CGCL revealed a significant association with the ratio of RANKL>OPG (p=0.001). Analysis of the bone resorption factors revealed no significant differences between aggressive and non-aggressive CGCL (p>0.05). It was observed a positive correlation between the markers themselves, and a negative correlation between lesion size and quantity of OPG positive MO cells (p=0,004) and total cells (p=0,009). Through these results, we suggest that the greatest CGCL resorptive potential compared to the PGCL, may have occurred to the high expression of RANKL. Furthermore differences in the biological behavior of aggressive and non-aggressive CGCL appear to be related to the expression of these bone resorption factors / As Les?es de C?lulas Gigantes, tanto as Les?es Centrais (LCCG) quanto as Perif?ricas (LPCG), correspondem a um grupo de les?es orais que apresentam-se histologicamente semelhantes, por?m demonstram um comportamento cl?nico vari?vel. O prop?sito deste estudo foi comparar a express?o imuno-histoqu?mica dos fatores de reabsor??o ?ssea RANK (Receptor Ativador do Fator Nuclear kappa B), RANKL (Ligante do Receptor Ativador do Fator Nuclear kappa B) e OPG (Osteoprotegerina) entre LCCG e LPCG. Adicionalmente, esses fatores foram analisados nas LCCG quanto ? agressividade destas. A amostra consistiu de 61 casos, sendo 30 casos de LPCG e 31 de LCCG (16 n?o-agressivos e 15 agressivos). A an?lise foi realizada por meio da quantifica??o das c?lulas mononucleadas (MO) e c?lulas gigantes multinucleadas (CG) imunopositivas aos anticorpos anti-RANK, anti-RANKL e anti-OPG, em 10 campos. Al?m disso, de acordo com a propor??o entre quantidade total de c?lulas positivas para RANKL e para OPG, os casos foram categorizados em: RANKL>OPG, OPG>RANKL e RANKL=OPG. As LCCG apresentaram maior quantidade de MO (p=0,002) e c?lulas totais (p=0,003) positivas para RANKL, em compara??o com as LPCG. As LCCG ainda revelaram uma associa??o significativa com a propor??o de RANKL>OPG (p=0,001). A an?lise dos fatores de reabsor??o ?ssea n?o revelou diferen?as significativas entre LCCG agressivas e n?o-agressivas (p>0,05). Foi constatada correla??o positiva dos marcadores entre si, bem como uma correla??o negativa entre o tamanho das les?es e a quantidade de MO (p=0,004) e c?lulas totais (p=0,009) positivas para OPG. Diante desses resultados, concluise que o maior potencial reabsortivo das LCCG frente ?s LPCG pode ser decorrente da elevada express?o de RANKL. Al?m disso, as diferen?as nos comportamentos biol?gicos de LCCG agressivas e n?o-agressivas parecem n?o estar relacionadas com a express?o desses fatores de reabsor??o ?ssea.